Repligen extends Protein A ligand supply deal with GE Healthcare

By Dan Stanton contact

- Last updated on GMT

Protein A OK! Image: iStock/oanav
Protein A OK! Image: iStock/oanav

Related tags: Protein

Protein A is essential in keeping the costs and complexity of purifying monoclonal antibodies down, says GE Healthcare as it extends its supply agreement with Repligen.

Massachusetts-based life sciences company Repligen manufactures Protein A ligands, a critical component of Protein A chromatography media, from its facilities in Lund, Sweden, and Waltham, Massachusetts.

The firm has been supplying bioprocessing tech firm GE Healthcare for over 15 years, but announced this week it has struck a deal to extend supply through to 2019 from the Swedish facility and 2021 from the US site.

“Repligen is one of the largest producers of Protein A ligands and GE has a long standing Strategic Supplier Alliance Agreement with them,” GE’s BioProcess Senior Product Manager Jonathan Royce told Biopharma-Reporter.com

They have an excellent track record of supplying us with Protein A ligands and have been recognized on several occasions as a top supplier to GE Healthcare.”

He added Repligen’s two separate manufacturing sites was also a key in the supply extension as it “aligns directly with GE’s overall Security of Supply program which ensures an uninterrupted supply of critical raw materials to our customers.”

Protein A

Despite the cost of Protein A, the efficacy of the resin in capturing antibodies in the downstream process is undeniable, and ensuring supply is essential as the biopharma world continues to focus on mAbs and Fc-fusion proteins, Royce continued.

“Protein A provides unmatched purity in a single purification step and allows companies to build purification platforms which simplify manufacturing and process development operations.

“Without Protein A, the purification of monoclonal antibodies would be far more complex and expensive than it is today.”

GE couples the ligands to its own agarose-based chromatography beads, and performs QC analysis and final filling of these products at its site in Uppsala, Sweden.

According to Royce, the Uppsala site is one of the largest in the world for the production of chromatography media, producing over 350,000 liters per year for its biopharma customers.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us

Products

View more

Webinars